Welcome to our dedicated page for Carl Zeiss Medit news (Ticker: CZMWY), a resource for investors and traders seeking the latest updates and insights on Carl Zeiss Medit stock.
The news feed for CARL ZEISS MEDI UNSP/ADR (CZMWY) tracks announcements and press releases from Carl Zeiss Meditec AG, a medical technology company focused on ophthalmology, eye disease treatment and microsurgical visualization. Company news highlights how Carl Zeiss Meditec develops and introduces technologies that span diagnostics, digital data platforms, surgical systems and therapeutic solutions.
Recent news has emphasized ophthalmic innovations such as expansions of the ZEISS Corneal Refractive Workflow and ZEISS Retina Workflow, including milestones in lenticule extraction solutions utilizing ZEISS SMILE and ZEISS SMILE pro, updates to VISUMAX 800 femtosecond laser systems, and regulatory approvals for devices like the MEL 90 excimer laser and CLARUS 700 fundus imaging system. The company also reports on AI-enabled tools such as the CIRRUS PathFinder clinical support tool and the ZEISS Research Data Platform, reflecting its focus on digitally connected and data-driven care.
Beyond ophthalmology, Carl Zeiss Meditec news includes developments in neurosurgery and oncology, such as FDA clearance for the INTRABEAM 700 intraoperative radiotherapy platform. Updates related to DORC, including vitreoretinal surgical systems and staining dyes like ILM-Blue, further illustrate the company’s role across the retina and posterior segment surgery landscape.
Investors and clinicians following CZMWY-related news can use this page to monitor product approvals, workflow enhancements, AI and digital platform launches, and clinical milestones that the company reports. Regularly reviewing these updates can provide context on how Carl Zeiss Meditec positions its technologies within ophthalmology, microsurgery and related medical fields.
ZEISS Medical Technology is showcasing new digital enhancements and surgical solutions at the American Academy of Ophthalmology (AAO) conference from Oct. 19-21, 2024, in Chicago. Key highlights include:
- Introduction of ZEISS VisioGen, an AI-driven solution for enhancing refractive patient communication and streamlining clinic operations
- Celebration of 10 million eyes treated with ZEISS SMILE and ZEISS SMILE pro lenticule extraction solutions
- Marking 25 years of leadership in optical biometry with ZEISS IOLMaster biometers
- Demonstration of the FDA-cleared ZEISS MICOR 700, the first hand-held lens removal device with ultrasound-free operation
- Expansion of the ZEISS Retina Workflow to include advanced vitreoretinal surgical solutions from DORC
- FDA clearance for next-generation ZEISS VISULAS combi and green therapeutic lasers
These innovations aim to advance clinical workflows and support personalized care across cataract, corneal refractive, retina, and glaucoma treatments.
ZEISS Medical Technology has launched the KINEVO® 900 S, its latest Robotic Visualization System® for neurosurgery, at the Congress of Neurological Surgeons in Houston. This system, an evolution of the successful ZEISS KINEVO 900 platform, offers enhanced digital visualization, collaborative assistant functions, and connected intelligence for complex surgical procedures.
Key features include:
- 4K 3D digital image quality with a new DepthPro Mode
- Hybrid visualization concept for uninterrupted workflow
- Cobotic assistant with AI-powered functions like AutoCenter
- Connected digital solutions for data management and collaboration
- ZEISS OPTIME complete+ service plan with 98% uptime guarantee
The KINEVO 900 S will be gradually available in all existing markets following its launch.
ZEISS Medical Technology has announced the broad U.S. distribution of the MICOR® 700, the first hand-held ultrasound-free lens removal device. This revolutionary device uses the ZEISS NULEX (non-ultrasonic lens extraction) procedure to broaden surgeons' intraocular working space, minimize risk to surrounding eye structures, and increase operating room efficiency.
Key features of the ZEISS MICOR 700 include:
- Patented crystalline lens extraction technology
- Blunt and rounded tip design
- Single-use "plug & play" system with minimal O.R. footprint
- Less thermal energy delivery than phaco
- Cavitation-free lens removal
- Disposable fluidics system to mitigate cross-contamination risk
The device is FDA approved and commercially available in the U.S. It will be demonstrated at the American Academy of Ophthalmology (AAO) conference from Oct. 19 – 21, 2024, in Chicago.
ZEISS Medical Technology is showcasing innovative solutions for retinal patient care at EURETINA 2024. Key highlights include:
- The ARTEVO 850 3D digital visualization system for ophthalmic surgery, offering customizable 3D visualization and integrated intraoperative OCT
- Single-use Lenses for ZEISS RESIGHT fundus viewing system
- The EVA NEXUS surgical system from DORC for vitreoretinal and cataract procedures
- CIRRUS PathFinder, an AI-based tool for efficient OCT data review
- A new spatial computing app for Apple Vision Pro, allowing surgeons to review 2D/3D surgery videos and patient information
These innovations aim to improve diagnosis, treatment efficiency, and patient outcomes in retinal care.
ZEISS Medical Technology is showcasing its latest innovations at the ESCRS conference, highlighting advancements in cataract and corneal refractive workflows. Key developments include:
1. ZEISS SMILE pro for hyperopia treatment in CE markets, with over 10 million eyes treated using ZEISS SMILE technology.
2. Introduction of advanced optical and digital ophthalmic microscopes: ZEISS ARTEVO 750 and ZEISS ARTEVO 850.
3. New clinical results for the AT ELANA 841P trifocal IOL.
4. AI advancements: ZEISS AI IOL Calculator (CE-marked) and CIRRUS PathFinder (pending CE mark) for improved pre-operative patient care.
5. ZEISS Surgery Optimizer with AI-based video segmentation for post-surgery analysis.
These innovations aim to enhance surgical workflows, improve patient outcomes, and pave the way for more personalized care in ophthalmology.
On May 30, 2024, ZEISS Medical Technology announced enhancements to its CIRRUS 6000 OCT device. These upgrades include the largest OCT reference database in the U.S. market, featuring data from 870 healthy eyes, and advanced cybersecurity features. Recently FDA-cleared, the CIRRUS 6000 aims to facilitate data-driven patient care and improve clinical workflows for ophthalmologists. Key features include high-speed imaging, a wide field of view, and advanced visualization tools for retina, glaucoma, and anterior segment analysis. The device also ensures secure, seamless data transfer from previous CIRRUS models, emphasizing efficiency and compliance in clinical settings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Carl Zeiss Medit (CZMWY)?
What is the market cap of Carl Zeiss Medit (CZMWY)?
